Published on Oct 22, 2020 at 12:52 PM
Updated on Oct 22, 2020 at 1:28 PM
  • Earnings Preview

Blue-chip pharmaceutical concern Pfizer Inc. (NYSE:PFE) is scheduled to report fiscal third-quarter earnings before the market opens on Tuesday, Oct. 27. It's purely coincidental that PFE will report a week before one of the most anticipated elections in U.S. history, especially after U.S. President Donald Trump made comments about an effective COVID-19 vaccine being ready before the election -- comments that Pfizer's CEO refuted concerning its own vaccine. Below, we'll take a look at Pfizer stock's technical setup, as well as its earnings history ahead of a important two week slate.

Although its a notable contender in the race to produce an effective coronavirus vaccine, Pfizer has struggled with its year-to-date breakeven point all 2020. There's support emerging at the $36 area, but overhead $39 --which roughly coincides with that aforementioned year-to-date level -- has stymied PFE's most recent breakout attempts in July and October.

PFE Stock Chart

Optimism is growing in the options pits, where calls are popular. This is per the blue chip's 10-day call/put volume ratio of 10.97 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which is two percentage points from an annual high. In other words, calls are being ordered up at a quicker-than-usual rate in the last two weeks.

PFE has a history of mixed responses following earnings, closing higher in four of the past eight quarters. This includes a 3.9% jump last July, but also a 5% drop last January. Over the past two years, shares have swung an average of 2.9% the day after earnings, regardless of direction. This time around, the options market is pricing in a slightly higher swing of 5.8%.

Published on Oct 20, 2020 at 9:49 AM
  • Buzz Stocks
Moderna said it plans on starting on finishing touches as soon as the potential treatment is approved for emergency use by the Food and Drug Administration (FDA), which could happen as soon as December.
Published on Oct 14, 2020 at 10:43 AM
  • Intraday Option Activity
  • Buzz Stocks
Options traders are responding in kind to today's news. Over 5,000 calls have changed hands already, double the average intraday amount and triple the number of puts traded. 
Published on Oct 13, 2020 at 11:09 AM
Updated on Oct 13, 2020 at 11:10 AM
  • Buzz Stocks
 However, separately, the company was forced to pause a clinical trial of its coronavirus vaccine candidate after a participant in the study came down with an unexplained illness. Johnson & Johnson stock is now down 1.7%, last seen trading at $149.24 this morning.
Published on Oct 7, 2020 at 10:42 AM
  • Analyst Update
  • Buzz Stocks
 
Published on Sep 23, 2020 at 10:59 AM
  • Buzz Stocks
 
Published on Sep 1, 2020 at 10:56 AM
  • Buzz Stocks
 
Published on Aug 31, 2020 at 9:59 AM
  • Buzz Stocks
On the charts, the stock has been extremely volatile as of late. Shares hit a three-year high of $85.97 on March 19, with another run at this peak in mid-April. 
Published on Aug 31, 2020 at 8:59 AM
  • Buzz Stocks
This move comes just a few months after a July report by the U.S. Congress House Subcommittee on Economic and Consumer Policy revealing that the White House overpaid for this order by at least $500 million, though the company denied any profiteering.
Published on Aug 27, 2020 at 11:24 AM
  • Intraday Option Activity
The test can deliver results within 15 minutes -- much shorter than the testing methods currently being used -- and will sell for $5. Abbott said it expects to ship 50 million tests one month from the beginning of October.  
Published on Aug 25, 2020 at 9:59 AM
  • Buzz Stocks
The company had warned it would need to furlough employees once the $25 billion in U.S. government stimulus runs out, but pilot union Air Line Pilots Association, International (ALPA) said they were disappointed in Delta's decision, and that management had decided to use "threat of furloughs to force acceptance of involuntary concessions." 
Published on Aug 24, 2020 at 10:02 AM
  • Buzz Stocks
From a technical standpoint,  it appears the stock's 10-day moving average has emerged as a ceiling on the charts, coming in shortly after MRNA's all-time high of $95.21 late last month

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
Special Offers from Schaeffer's Trading Partners

MORE | MARKETstories


Are You Prepared for the Biggest Market Event of the Decade?
This former hedge fund manager is exposing how Wall Street is failing American investors, and helping them realize they need to get out of cash now
Busy Pre-Election Week Ahead With Big-Name Earnings
Vaccine candidates Eli Lilly, Gilead, Pfizer, and Moderna will all report earnings next week
DGX Gains on Q3 Beat, Raised Guidance
The company reported earnings and revenue above analyst expectations
Where Is the Market Bottom?
Learn how to navigate these unstable market conditions